

Come Transform Research™

#

**For Immediate Release:**

February 22, 2016

**Contact Information:**

Tom Manning, Director of Marketing Communications

Telephone: +1.630.256.7527, ext. 103

E-mail: [tmanning@slas.org](mailto:tmanning@slas.org)

### **Modulation of NF-κB Signaling as a Therapeutic Target in Autoimmunity**

**CHICAGO** –A new review article published in the March 2016 issue of the *Journal of Biomolecular Screening (JBS)* details the role and therapeutic potential of NF-κB in autoimmune disease. There are numerous autoimmune diseases, and numerous pathways that can be activated or inhibited, which result in overt pathology. However, it is becoming apparent that in a proportion of autoimmune diseases there are common cellular and molecular pathways that link them.

One such pathway is NF-κB. The modulation of NF-κB is an appealing target for the treatment of autoimmune disease but unfortunately none have yet progressed to the clinic. The review is authored by Carl Goodyear, PhD, FRBS, director of the GLAZgo Discovery Centre and reader at the University of Glasgow; and Felicity Herrington and Ruaidhri Carmody of the Centre of Immunobiology at the University of Glasgow.

With increased interest in targeting autoimmune diseases, novel NF-κB therapies are being explored by a large number of companies and academic institutes. The review describes the most promising directions, covering all existing treatment modalities, such as small molecules, proteins and RNA. The review also provides a comprehensive summary of the NF-κB pathways, including the points of regulation that could serve as potential entry points for a therapeutic intervention. Among these are deubiquitinating enzymes inhibitors, E3 ligase inhibitors, proteasome inhibitors and modulation of NF-κB DNA binding. Finally, it also provides details of the important considerations that need to be taken into account when designing new therapies that are aimed at targeting NF-κB.

JBS is one of two MEDLINE-indexed scientific journals published by SLAS (Society for Laboratory Automation and Screening). Visit JBS Online at <http://jbx.sagepub.com/content/21/3> to read “Modulation of NF-κB Signaling as a Therapeutic Target in Autoimmunity.” For more information about SLAS and its journals, visit [www.slas.org/jala-jbs](http://www.slas.org/jala-jbs).

\* \* \* \* \*

**SLAS (Society for Laboratory Automation and Screening)** is an international community of more than 20,000 individual scientists, engineers, researchers, technologists and others from academic, government and commercial laboratories. The SLAS mission is to be the preeminent global organization providing forums for

---

**SLAS GLOBAL HEADQUARTERS**

100 Illinois Street, Suite 242  
St. Charles, IL 60174, USA  
P: +1.630.256.7527  
US Toll Free: +1.877.990.SLAS (7527)  
[slas@slas.org](mailto:slas@slas.org)  
[www.SLAS.org](http://www.SLAS.org)

**SLAS ASIA OFFICE**

[asia@slas.org](mailto:asia@slas.org)  
[www.Asia-SLAS.org](http://www.Asia-SLAS.org)

**SLAS EUROPE OFFICE**

[europe@slas.org](mailto:europe@slas.org)  
[www.Europe-SLAS.org](http://www.Europe-SLAS.org)

education and information exchange and to encourage the study of, and improve the practice of life sciences discovery and technology. For more information, visit [www.SLAS.org](http://www.SLAS.org).

SLAS publishes two internationally recognized, MEDLINE-indexed journals, now in their 21st year of publication. **The Journal of Laboratory Automation (JALA)** and **Journal of Biomolecular Screening (JBS)** uniquely serve life sciences discovery and technology professionals. Together, JALA and JBS address the full spectrum of issues that are mission-critical to this important audience, enabling scientific research teams to gain insights, increase productivity, elevate data quality, reduce lab process cycle times and enable experimentation that otherwise would be impossible.

Specifically, **JALA** explores ways in which scientists adapt advancements in technology for scientific exploration and experimentation. In direct relation to this, **JBS** reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease.

**Journal of Biomolecular Screening (JBS):** 2013 Impact Factor 2.423. Editor-in-Chief Robert M. Campbell, Ph.D., Eli Lilly and Company, Indianapolis, IN (USA).

**Journal of Laboratory Automation (JALA):** 2013 Impact Factor 1.879. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore).